Related Experiment Videos
[Streptokinase treatment in acute myocardial infarction]
Insights
Early fibrinolytic treatment with streptokinase can limit myocardial infarction size and reduce mortality by 25%. Prompt administration, especially within one hour of chest pain, is crucial for preserving heart function and preventing infarction.
Area of Science:
- Cardiology
- Thrombosis
- Pharmacology
Context:
- Myocardial infarction (MI) results from coronary artery occlusion and gradual necrosis.
- Thrombi frequently precipitate MI, making early reperfusion therapy critical.
- Current treatment strategies aim to limit infarct size and preserve myocardial function.
Purpose:
- To evaluate the efficacy of early fibrinolytic treatment with streptokinase in managing acute myocardial infarction.
- To determine the optimal timing and route of streptokinase administration.
- To assess the impact of streptokinase on infarct size, myocardial function, and mortality.
Summary:
- Intracoronary or intravenous streptokinase achieves recanalization in most patients.
- Early streptokinase treatment limits infarct size and improves myocardial function preservation.
- Very early treatment (within 1 hour) may prevent infarction and significantly reduces mortality (up to 25%).
Impact:
- Intravenous streptokinase is recommended for patients with nitroglycerin-resistant chest pain and abnormal ECG, unless contraindicated.
- Acetylsalicylic acid should be co-administered to most patients receiving streptokinase.
- Early fibrinolytic therapy with streptokinase offers significant survival benefits and functional recovery in MI patients.
Abstract:
Myocardial necrosis develops gradually after coronary artery occlusion, and in man is completed after several hours. Most infarctions are precipitated by thrombi, and early fibrinolytic treatment should therefore be the rational therapy. Recanalization is achieved in three of four patients whether streptokinase is applied intracoronary or intravenously. Early treatment limits the size of the infarct, and he myocardial function is preserved better in patients treated with streptokinase than in others. Very early treatment, started within one hour from the onset of nitroglycerin-resistant chest pain, may prevent infarction in some patients. Streptokinase reduces mortality after infarction, in total by as much as 25 per cent, and even considerably more when infusion is started early. There is some risk of bleeding, but serious bleeding episodes are rare. Intracoronary application has no advantages as compared with intravenous infusion. Unless there are strong contra-indications, patients with nitroglycerin-resistant chest pain and abnormal ECG should receive streptokinase intravenously in a dose of 1.5 x 10(6) units. Most patients treated with streptokinase should be given acetylsalicylic acid.